24/04/2014 01:29:38 Free Membership Login

Akers Biosciences Company Financial Information

 Company name: Akers Bio(Regs)
 EPIC: AKR Trading Currency: GBX
 Market Sector: AIM ISIN: US00973E1029
 Market Segment: AIM Share Type: DE
 WWW Address: http://www.akersbiosciences.com/ Description: COM SHS NPV (REG S)
 Price Price Change [%] Bid Ask Open High Low Volume
 265.00 mages.advfn.com/imagesnew/2/us/dot 0.0 [0.00] 250.00 280.00 265.00 265.00 265.00 26
 Market Cap. [m] Shares In Issue [m] Beta EPS DPS PE Ratio Yield 52-Wks-Range
 12.97 4.89 -26.77 -57.21 - - - 663.75 - 157.50

Akers Biosciences Key Figures

(at previous day's close)
Market Cap.12.97m
Shares In Issue4.89m
Prev. Close265.00
PE Ratio- 
Dividend Yield-%
EPS - basic-57.21p
Dividend PS-p
Dividend Cover- 
Cash Flow PS-33.69p
Return On Equity (ROE)-37.04%
Operating Margin-42.67%
PEG Factor- 
EPS Growth Rate-%
Dividends PS Growth Rate-%
Net Debt1.12m
Gross Gearing32.15%
Quick Assets1.42m
Net Working Capital0.86m
Intangibles / Fixed Assets89.96%
Turnover PS44.15p
Pre-Tax Profit PS-18.84p
Retained Profit PS-18.84p
Cash PS1.28p
Net Cash PS-22.82p
Net Tangible Asset Value PS *20.82p
Net Asset Value PS50.86p
Spread30.00 (10.71%) 

Akers Biosciences Balance Sheet


Akers Biosciences Share Price

Sample Period HighLow
1 week265.00265.00
4 weeks300.00265.00
12 weeks370.00265.00
1 year663.75157.50

Akers Biosciences Share Price (5 years)

Akers Biosciences Historic Returns

Giorni da oggi OpenChange%Open Avg.Avg. Daily Vol [m]Total Vol [m]VWAP
1 week265.00--265.000.00265.00
4 weeks290.00-25.00-8.62282.220.01275.71
12 weeks367.50-102.50-27.89326.210.00315.91
26 weeks648.75-383.75-59.15420.2728.88602.36
1 year236.2528.7512.17326.5864.03372.77
3 years600.00-335.00-55.83276.4442.31310.80
5 years3,900.00-3,635.00-93.21916.9238.83752.95

Akers Biosciences Key Management Ratios

Akers Biosciences Investment Ratios

(Market value analysis) at previous day's close
PQ Ratio- 
PE Ratio- 
Tobin's Q Ratio 2.08 
Tobin's Q Ratio (excl. intangibles)4.08 
Dividend Yield-%
Market-to-Book Ratio5.21 
Price-to-Pre-Tax Profit PS-14.07 
Price-to-Retained Profit PS-14.07 
Price-to-Cash Flow PS-7.87 
Price-to-Sales PS6.00 
Price-to-Net Tangible Asset Value PS12.73 
Price-to-Cash PS207.24 
Net Working Capital PS17.47 
Price Pct to Working Capital PS15.17%
Earnings Yield-%
Average PE- 
Years in average- 
PE to PE average-%

Akers Biosciences Financial Ratios

(Leverage Ratios)
Debt Ratio-%
Debt-to-Equity Ratio- 
Debt-to-Equity Ratio (excl. Intgbl)- 
Debt-to-Equity Market Value- 
Net Gearing30.45%
Net Gearing (excl. Intangibles)50.80%
Gross Gearing32.15%
Gross Gearing (excl. Intangibles)53.65%
Gearing Under 1 Year32.15%
Gearing Under 1 Year (excl. Intgbl)53.65%
(Liquidity Ratios)
Net Working Capital to Total Assets23.31%
Current Ratio1.72 
Quick Ratio (Acid Test)1.20 
Liquidity Ratio0.05 
Cash & Equiv/Current Assets3.08%
(Solvency Ratios)
Enterprise Value12.91m
CFO/Attributable Profit- 
Total Debt/Equity Market Value0.09 
Total Debt/Sales0.55 
Total Debt/Pre-Tax Profit-1.28 
Total Debt1.18m
Total Debt/Net Current Assets1.38%
(Dodds - Graham Ratios)
3 yr Compound Earnings Growth-%
5 yr Compound Earnings Growth-%
10 yr Compound Earnings Growth-%
Earn drops > 5% in 10yrs4 
Beta (60-Mnth)Beta (36-Mnth)
Alpha (60-Mnth)Alpha (36-Mnth)

Akers Biosciences Operating Ratios

(Profitability Ratios)
Return On Capital Employed (ROCE)-37.04%
Return On Assets (ROA)-14.76%
Net Profit Margin-42.67%
Assets Turnover0.35 
Return On Equity (ROE)-37.04%
Return On Investment (ROI)-21.89%
Dividend Payout Ratio-%
Plowback Ratio100.00%
Growth from Plowback Ratio-%
Net Income Of Revenues-42.67%
(Asset Utilisation Multiples)
Shareholders Equity Turnover0.51 
Fixed Assets Turnover0.65 
Current Assets Turnover0.74 
Net Working Capital Turnover 
Inventory Turnover2.15 
(Other Operating Ratios)
Total Assets-to-Sales2.89 
Debt Collection Period242.17Days

Akers Biosciences Dividends

Sorry No Data Available

Akers Biosciences Fundamentals

 31 Dec 2010 (USD)31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)
pre tax profit-1.20-39.41%-3.88-217.48%-2.71-177.90%-1.53-42.67%m
attributable profit-0.92-30.13%-3.58-200.79%-2.54-166.90%-1.53-42.67%m
retained profit-0.92-30.13%-3.58-200.79%-2.54-166.90%-1.53-42.67%m
eps - basic-1.00 -2.00 -1.00 -96.00 
eps - diluted-1.00 -2.00 -1.00 -96.00 
dividends per share- - - - 

Akers Biosciences Balance Sheet

 31 Dec 2010 (USD)31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)
 31 Dec 2010 (USD)31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)
fixed assets fixed assets0.435.62%0.344.96%0.243.74%0.274.40%m
intangibles intangibles2.0626.66%3.9357.16%3.6957.55%2.4340.07%m
fixed investments fixed investments0.000.06%0.000.07%0.000.07%0.000.07%m
current assets - other current assets - other0.081.06%0.081.23%0.071.06%0.162.70%m
stocks stocks0.698.88%0.699.96%0.9915.39%1.0316.87%m
debtors debtors4.0352.23%0.649.29%0.7912.32%2.0834.18%m
cash & securities cash & securities0.425.48%1.1917.33%0.639.86%0.101.71%m
creditors - short creditors - short1.2716.47%0.7110.38%2.1132.93%1.9532.15%m
creditors - long creditors - long--%--%--%--%m
creditors - other creditors - other--%--%--%--%m
subordinated loans subordinated loans--%--%--%--%m
insurance funds insurance funds--%--%--%--%m
ord cap, reserves ord cap, reserves6.4583.53%6.1789.62%4.3067.07%4.1267.85%m
prefs, minorities prefs, minorities--%--%--%--%m
NAV Basic- - - - 
NAV Diluted- - - - 

Akers Biosciences Cash Flow Statement

31 Dec 2010 (USD)31 Dec 2011 (USD)31 Dec 2012 (USD)31 Dec 2013 (USD)
Operating CF-1.73-2.26-0.82-2.73m
Pre-Financing CF-2.25-2.51-1.01-2.66m
Retained CF-2.230.77-0.56-0.53m

Akers Biosciences Brokers

Arbuthnot Securities LimitedMarket Maker(MMF)Broker/DealerARBTALESGB31MKT
Commerzbank AGMarket Maker(MMF)Broker/DealerKLWTDRESGB2LPST
Evolution Securities LimitedMarket Maker(MMF)Broker/DealerEVOEVBGGB21MMT
Jefferies International LtdMarket Maker(MMF)Broker/DealerJEFFJEFFGB2X
Shore Capital Stockbrokers LtdMarket Maker(MMF)Broker/DealerSCAPSHOCGB21
Winterflood Securities LtdMarket Maker(MMF)Broker/DealerWINSWNTSGB2LBIC

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us lse akr140424 01:29